CVD EQUIPMENT CORP 10-Q

Item 1 – Financial Statements CVD EQUIPMENT CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share amounts) (Unaudited) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 11,893 $ 14,025 Accounts receivable, net of allowance for credit losses 2,971 1,906 Contract assets 2,689 1,604 Inventories 4,925 4,454 Other current assets 858 852 Total current assets 23,336 22,841 Property, plant and equipment, net 12,089 12,166 Other assets 18 18 Total assets $ 35,443 $ 35,025 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,798 $ 1,203 Accrued expenses 1,690 1,765 Current maturities of long-term debt 83 81 Deposit from purchaser of MesoScribe assets-Note 11 597 597 Contract liabilities 6,030 4,908 Total current liabilities 10,198 8,554 Long-term debt, net of current portion 247 268 Total liabilities 10,445 8,822 Contingencies – Note 12 - - Stockholders’ equity: Common stock - $ 0.01 par value – 20,000,000 shares authorized; 6,824,511 issued and outstanding at March 31, 2024 and December 31, 2023 68 68 Additional paid-in capital 28,962 28,695 Accumulated deficit ( 4,032 ) ( 2,560 ) Total stockholders’ equity 24,998 26,203 Total liabilities and stockholders’ equity $ 35,443 $ 35,025 The accompanying notes are an integral part of these condensed consolidated financial statements 3 CVD EQUIPMENT CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Operations (in thousands, except per share and share amounts) (Unaudited) 2024 2023 Three Months Ended March 31, 2024 2023 Revenue $ 4,922 $ 8,695 Cost of revenue 4,063 6,261 Gross profit 859 2,434 Operating expenses: Research and development 746 602 Selling 419 419 General and administrative 1,317 1,600 Total operating expenses 2,482 2,621 Operating loss ( 1,623 ) ( 187 ) Other income (expense): Interest income 157 120 Interest expense ( 6 ) ( 6 ) Foreign exchange income - 27 Other income - 8 Total other income, net 151 149 Loss before income taxes ( 1,472 ) ( 38 ) Income tax expense - 2 Net loss $ ( 1,472 ) $ ( 40 ) Loss per common share - basic $ ( 0.22 ) $ ( 0.01 ) Loss per common share - diluted $ ( 0.22 ) $ ( 0.01 ) Weighted average common shares outstanding: Basic 6,809,283 6,773,285 Diluted 6,809,283 6,773,285 The accompanying notes are an integral part of these condensed consolidated financial statements 4 CVD EQUIPMENT CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Changes in Stockholders’ Equity (in thousands, except share amounts) (Unaudited) Three months ended March 31, 2024 and 2023 Shares Par Value Capital Earnings Total (Accumulated Common stock Additional paid-in Deficit) Retained Shares Par Value Capital Earnings Total Balance at January 1, 2024 6,824,511 $ 68 $ 28,695 $ ( 2,560 ) $ 26,203 Net loss - - - ( 1,472 ) ( 1,472 ) Stock-based compensation - - 267 - 267 Balance at March 31, 2024 6,824,511 $ 68 $ 28,962 $ ( 4,032 ) $ 24,998 Balance at January 1, 2023 6,760,938 $ 67 $ 27,712 $ 1,620 $ 29,399 Balance 6,760,938 $ 67 $ 27,712 $ 1,620 $ 29,399 Net loss - - - ( 40 ) ( 40 ) Stock-based compensation - - 135 - 135 Exercise of stock options and issuance of shares 17,500 - 73 - 73 Balance at March 31, 2023 6,778,438 $ 67 $ 27,920 $ 1,580 $ 29,567 Balance 6,778,438 $ 67 $ 27,920 $ 1,580 $ 29,567 The accompanying notes are an integral part of these condensed consolidated financial statements 5 CVD EQUIPMENT CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) 2024 2023 Three Months Ended March 31, 2024 2023 Cash flows from operating activities: Net loss $ ( 1,472 ) $ ( 40 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 267 135 Depreciation and amortization 153 166 Changes in assets and liabilities: Accounts receivable ( 1,065 ) 1,420 Contract assets ( 1,085 ) ( 1,537 ) Inventories ( 471 ) ( 262 ) Other current assets ( 28 ) 119 Accounts payable 611 ( 25 ) Accrued expenses ( 75 ) ( 467 ) Contract liabilities 1,122 ( 2,781 ) Net cash used in operating activities ( 2,043 ) ( 3,272 ) Cash flows from investing activities: Purchases of property and equipment ( 70 ) ( 146 ) Net cash used in investing activities ( 70 ) ( 146 ) Cash flows from financing activities: Repayments of long-term debt ( 19 ) ( 19 ) Proceeds from exercise of stock options - 73 Net cash (used in) provided by financing activities ( 19 ) 54 Net decrease in cash and cash equivalents ( 2,132 ) ( 3,364 ) Cash and cash equivalents at beginning of period 14,025 14,365 Cash and cash equivalents at end of period $ 11,893 $ 11,001 Supplemental disclosure of cash flow information: Income taxes paid $ - $ 8 Interest paid $ 6 $ 6 The accompanying notes are an integral part of these condensed consolidated financial statements 6 CVD EQUIPMENT CORPORATION AND SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (Unaudited) NOTE 1: BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements for CVD Equipment Corporation and Subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. They do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the interim financials not misleading have been included and all such adjustments are of a normal recurring nature. The operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that can be expected for the year ending December 31, 2024. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at such date, as filed on Form 10-K with the SEC on March 28, 2024, but does not contain all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with that report. All material intercompany balances and transactions have been eliminated in consolidation. Reclassifications Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss. . Liquidity At March 31, 2024, the Company had $ 11.9 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these condensed consolidated financial statements.. 7 NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606 ” ), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606 , the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods: Over time The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time. Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the three months ended March 31, 2024 and 2023. The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones. 8 NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract. Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer. Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured. Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months. Point in time For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.” For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the three months ended March 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method. Inventories Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory. 9 NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made. Product Warranty The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the condensed consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred . Recent Accounting Standards In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures ,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 may have on our consolidated financial statements. 10 NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 may have on our consolidated financial statements. The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting. NOTE 3: CONCENTRATION OF CREDIT RISK Cash and cash equivalents The Company had cash and cash equivalents of $ 11.9 million and $ 14.0 million at March 31, 2024 and December 31, 2023, respectively. The Company invests excess cash in U.S. treasury bills, certificates of deposit or deposit accounts, all with maturities of less than three months. Cash equivalents were $ 11.1 million and $ 12.1 million at March 31, 2024 and December 31, 2023, respectively. The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at March 31, 2024 and December 31, 2023 was $ 0.3 million and $ 1.5 million, respectively. 11 NOTE 3: CONCENTRATION OF CREDIT RISK (continued) Accounts receivable The Company routinely assesses the financial strength of its customers . In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts . The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts. Accounts receivable is presented net of an allowance for credit losses of $ 36,000 as of both March 31, 2024 and December 31, 2023. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition. At March 31, 2024, the accounts receivable balance included an amount from one customer that totaled 67.2 % of total accounts receivable. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6 %, 13.0 % and 12.8 % of total accounts receivable . Sales concentration Revenue from a single customer in any one period can exceed 10% of our total revenues. During the three months ended March 31, 2024, two customers exceeded 10% of revenues, representing 29.6 % and 13.1 % of revenues, and during the three months ended March 31, 2023, three customers exceeded 10%, representing 28.3 %, 15.9 % and 10.6 % of revenues. 12 NOTE 4: REVENUE RECOGNITION The following table represents a disaggregation of revenue for the three months ended March 31, 2024 and 2023 (in thousands): Schedule of Disaggregation of Revenue Over time Point in time Total Three months ended March 31, 2024 Over time Point in time Total Energy $ - $ 18 $ 18 Aerospace 1,802 332 2,134 Industrial 1,259 483 1,742 Research 861 167 1,028 Total $ 3,922 $ 1,000 $ 4,922 Over time Point in time Total Three months ended March 31, 2023 Over time Point in time Total Energy $ 2,516 $ 14 $ 2,530 Aerospace 264 251 515 Industrial 3,670 213 3,883 Research 1,272 495 1,767 Total $ 7,722 $ 973 $ 8,695 The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. The research market principally represents customers that are universities and other research institutions. The Company has unrecognized contract revenue of approximately $ 24.8 million at March 31, 2024, which it expects to substantially recognize as revenue within the next eighteen months. Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize. Changes in estimates for sales of systems may occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated statements of operations. 13 NOTE 4: REVENUE RECOGNITION (continued) Contract assets and liabilities Contract assets and contract liabilities on input method type contracts in progress are summarized as follows as of March 31, 2024 (in thousands): Schedule of Cost and Estimated Earnings in Excess of Billings Costs incurred on contracts in progress $ 10,024 Estimated earnings 4,582 Costs and estimated earnings on uncompleted contracts $ 14,606 Billings to date ( 17,649 ) Net cost in excess of billings ( 3,043 ) Deferred revenue related to non-system contracts and a system contract to be recognized at point in time ( 298 ) Contract liability in excess of contract assets $ ( 3,341 ) Included in accompanying condensed consolidated balance sheets under the following captions (in thousands): Contract assets $ 2,689 Contract liabilities $ 6,030 Of the contract liability balances at December 31, 2023 and 2022 of $ 4.6 million and $ 4.1 million, respectively, $ 1.3 million and $ 2.9 million was recognized as revenue during the three months ended March 31, 2024 and 2023, respectively. NOTE 5: INVENTORIES, NET Schedule of Inventories, Net Inventories consist of: March 31, 2024 December 31, 2023 Raw materials $ 2,507 $ 2,351 Work-in-process 1,563 1,248 Finished goods 855 855 Total $ 4,925 $ 4,454 NOTE 6: LONG-TERM DEBT In September 2022, the Company entered into a loan agreement to fund the acquisition of machinery. The loan amount of $ 432,000 , is payable in 60 equal monthly installments of $ 8,352 and secured by equipment. The interest rate is 6 %. 14 NOTE 7: EARNINGS PER SHARE The calculation of basic and diluted weighted average common shares outstanding for the three months ended March 31, 2024 and 2023 is as follows: Schedule of Basic and Diluted Weighted Average Common Shares Outstanding 2024 2023 Three months ended March 31, 2024 2023 Basic weighted average common shares outstanding 6,809,283 6,773,285 Effect of potentially dilutive share-based awards - - Diluted weighted average shares outstanding 6,809,283 6,773,285 At March 31, 2024, stock options to purchase 841,875 shares of common stock were outstanding and 395,625 were exercisable. At March 31, 2023, stock options to purchase 899,500 shares of common stock were outstanding and 252,375 were exercisable. For the three months ended March 31, 2024 and 2023, 841,875 and 899,500 of stock options, respectively, were not included in the computation of diluted earnings per share because their effect was antidilutive. NOTE 8: STOCK-BASED COMPENSATION EXPENSE The Company recorded stock-based compensation for the three months ended March 31, 2024 and 2023, respectively, that were included in the following line items in our condensed consolidated statements of operations (in thousands): Schedule of Stock Based Compensation expense 2024 2023 Three months ended March 31, 2024 2023 Cost of revenue $ 38 $ 19 Research and development 47 20 Selling 27 11 General and administrative 155 85 Total $ 267 $ 135 15 NOTE 8: STOCK-BASED COMPENSATION EXPENSE (continued) Stock-based compensation expense included $ 50,000 and $ 40,000 for the three months ended March 31, 2024 and 2023, respectively, related to restricted stock awards that directors elected to receive pursuant to the Director Compensation plan. Under this plan, each of the five independent directors is entitled to an Annual Equity Retainer in the amount of $ 40,000 , to be granted on the date of the Company’s annual meeting of shareholders. For the three months ended March 31, 2024, the Company granted 5,000 stock options, vesting 25 % per year over four years , with a ten-year life. The Company determined the weighted average fair value of stock options granted was $ 3.30 and is based upon weighted average assumptions below. Schedule of Weighted Average Assumptions Stock price $ 4.75 Exercise price $ 4.75 Dividend yield 0 % Expected volatility 77 % Risk-free interest rate 4.12 % Expected life (in years) 6.00 The following table summarizes stock options awards for the three months ended March 31, 2024: Schedule of Stock Options Awards Weighted Stock Option Average Awards Exercise (in shares) Price Outstanding at January 1, 2024 846,875 $ 8.20 Granted 5,000 4.75 Forfeited ( 10,000 ) 8.01 Outstanding at March 31, 2024 841,875 8.18 The following table summarizes information about the outstanding and exercisable options at March 31, 2024 by ranges of exercise prices: Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices Options Outstanding Options Exercisable Weighted Weighted Weighted Average Average Average Exercise Number Remaining Exercise Intrinsic Number Exercise Intrinsic Price Range Outstanding Contractual Price Value Exercisable Price Value $ 4.00 - 7.00 462,125 7.6 $ 4.55 $ 144,275 194,750 $ 4.48 $ 68,931 $ 7.01 - 10.00 20,000 4.1 $ 8.07 $ - 20,000 $ 8.07 $ - $ 10.01 - 13.00 130,000 3.4 $ 10.62 $ - 122,500 $ 10.55 $ - $ 13.01 - 16.00 229,750 9.0 $ 14.11 $ - 58,375 $ 14.11 $ - 16 NOTE 8: STOCK-BASED COMPENSATION EXPENSE (continued) As of March 31, 2024, there was $ 2.2 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 2.0 years. NOTE 9: INCOME TAXES As of March 31, 2024 and December 31, 2023, the Company has provided a full valuation allowance against its net deferred tax assets. This was based on management’s assessment, including operating losses in recent years, that it is more likely than not that the net deferred tax assets may not be realized in the future. Management continues to evaluate for potential utilization of the Company’s net deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections of future operating results. NOTE 10: SEGMENT REPORTING The Company operates through three segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. The SDC segment designs and manufactures ultra-high purity gas and chemical delivery control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications and is not considered a core business of the Company. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes. The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for options and shares of restricted stock granted to corporate administration employees and board members, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees. Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales for the three months ended March 31, 2024 and 2023 by the SDC segment to the CVD Equipment segment were $ 15,000 and $ 129,000 , respectively. 17 NOTE 10: SEGMENT REPORTING (continued) The following table presents certain information regarding the Company’s segments as of and for the three months ended March 31, 2024 and 2023 (in thousands): Schedule of Segments CVD Equipment SDC CVD Materials Eliminations Corporate Consolidated 2024 CVD Equipment SDC CVD Materials Eliminations Corporate Consolidated Assets $ 31,412 $ 3,882 $ 183 $ ( 34 ) $ - $ 35,443 Revenue $ 2,947 $ 1,931 $ 59 $ ( 15 ) $ - $ 4,922 Operating (loss) income ( 1,405 ) 632 ( 25 ) - ( 825 ) ( 1,623 ) Pretax (loss) income ( 1,411 ) 632 ( 25 ) - ( 668 ) ( 1,472 ) Depreciation and amortization $ 141 $ 12 $ - $ - $ - $ 153 Purchase of property, plant & equipment $ 76 $ - $ - $ - $ - $ 76 CVD Equipment SDC CVD Materials Eliminations Corporate Consolidated 2023 CVD Equipment SDC CVD Materials Eliminations Corporate Consolidated Assets $ 28,509 $ 4,467 $ 1,783 $ 25 $ - $ 34,784 Revenue $ 5,845 $ 2,312 $ 667 $ ( 129 ) $ - $ 8,695 Operating (loss) income ( 95 ) 631 81 - ( 804 ) ( 187 ) Pretax (loss) income ( 93 ) 631 108 - ( 684 ) ( 38 ) Depreciation and amortization $ 131 $ 12 $ 23 $ - $ - $ 166 Purchase of property, plant & equipment $ 136 $ 10 $ - $ - $ - $ 146 18 NOTE 11: MESOSCRIBE SUBSIDIARY On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $ 0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones. The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. The Company received payments under the Agreement in the amount of $ 0.6 million which has been reflected as “deposit from purchaser” in the accompanying consolidated balance sheet as of March 31, 2024 and December 31, 2023. The Company expects the transaction to be completed in 2024 with the acceptance of the equipment by the purchaser. The revenues and net loss of MesoScribe were $ 59,000 and ($ 25,000 ) for the three months ended March 31, 2024. The total assets and total liabilities of the MesoScribe subsidiary were $ 0.2 million and $ 0.7 million, respectively, as of March 31, 2024 and $ 0.2 million and $ 0.7 million, respectively, as of December 31, 2023. NOTE 12: RISKS AND UNCERTAINTIES The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included: ● Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions. ● Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes. While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows. 19